We conducted a global anti-corruption compliance risk assessment for a publicly-traded international medical device company. The results of this assessment, including the suggested compliance program improvements, were key factors in the DOJ’s decision to not criminally prosecute the company nor require any type of corporate monitoring. This compliance program risk assessment including extensive interviews of international personnel in various corporate functions, review of documents, forensic accounting analysis, and reporting our results to the DOJ.
FCPA Compliance Risk Assessment for Medical Device Company
You Also May Be Interested In:
Representation of Lineagen, Inc., a provider of molecular diagnostics services for individuals showing clinical presentations consistent with neurodevelopmental disorders, in its sale to Bionano Genomics, Inc. (Nasdaq: BNGO), a genome analysis company providing tools and services to scientists and clinicians conducting genetic research and patient testing, for $9.6 million
Served as regulatory and deal counsel to BioPlus, a leading national specialty pharmacy, and ProHealth Pharmacy Solutions, a significant provider of infusion pharmacy management services in their sale to CarepathRx a platform company formed by Nautic Partners
Representation of Lincare Holdings, Inc., a nationwide healthcare services organization and a Florida-based subsidiary of German multinational chemical company Linde AG, in its sale of their home infusion assets to KabaFusion, a provider of specialty acute and chronic home infusion therapies